Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04202965 · ClinicalTrials.gov registry record · Phase 2
PTG-300 in Subjects With Hereditary Hemochromatosis
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT04202965: Completed Phase 2 study, sponsored by Protagonist Therapeutics.
NCT04202965 is a Phase 2 study that has completed, run by Protagonist Therapeutics. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04202965, a Phase 2 study, has completed, sponsored by Protagonist Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
Primary Outcome
Change from Baseline to Week 24 (or End of Treatment) in transferrin saturation (TSAT) as measured by blood laboratory tests.
Interventions
- DRUG PTG-300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-03-19 |
| Est. Completion | 2022-02-15 |
| Phase | Phase 2 |
What the finished NCT04202965 record still lists
NCT04202965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which PTG-300 is the first listed.
NCT04202965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04202965 about?
NCT04202965 is a clinical study titled "PTG-300 in Subjects With Hereditary Hemochromatosis". This study will be conducted at multiple sites and every patient will get treated with PTG-300. The objective of the study is to assess the effect of PTG-300 in treating adult hereditary hemochromatosis patients.
What is the current status of trial NCT04202965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2020-03-19. Estimated completion is 2022-02-15.
What interventions are being tested in trial NCT04202965?
The interventions under investigation include: PTG-300 (DRUG).
Who is sponsoring clinical trial NCT04202965?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04202965's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI